Senior author Mary Philip, MD, PhD, associate director of the Vanderbilt Institute for Infection, Immunology and Inflammation, talks about her Journal for ImmunoTherapy of Cancer study. The findings support further vaccine investigation to make long-term, progression-free survival a reality for more cancer patients.

The consortium is coordinated by the International Agency for Research on Cancer with the aim of sharing data from ongoing lung cancer case-control and cohort studies.

The therapy, P-BCMA-ALL01, demonstrated a 91% overall response rate for the 23 patients participating in the phase 1 trial.

The high-energy fundraiser began in 2022 to raise money for cancer initiatives at Vanderbilt-Ingram Cancer Center and Monroe Carell Jr. Children's Hospital at Vanderbilt.

The study seeks to understand the mechanisms of colorectal cancer and builds on recent Vanderbilt research.

The project seeks to reduce the time for clinical chart abstraction by 90% while maintaining human-level accuracy.

Launched Sept. 17-19 during the World Cancer Congress in Geneva, Switzerland, “Rewriting Cancer” aims to enhance understanding and inspire audiences by exploring the most innovative, inclusive and impactful solutions for cancer prevention, diagnosis, treatment and care globally.